多黏菌素B在腹部手术患者静脉给药后的腹膜穿透情况。你提供的原文中药物名称有误，原文中的“doripenem”是多立培南，而按照你译文来看，药物名称应该是“多黏菌素B（Polymyxin B）” ，我按照正确的原文翻译为：多立培南在腹部手术患者静脉给药后的腹膜穿透情况。

Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients.

作者信息

Ikawa Kazuro, Morikawa Norifumi, Urakawa Nami, Ikeda Kayo, Ohge Hiroki, Sueda Taijiro

机构信息

Department of Clinical Pharmacotherapy, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.

出版信息

J Antimicrob Chemother. 2007 Dec;60(6):1395-7. doi: 10.1093/jac/dkm371. Epub 2007 Sep 19.

DOI:10.1093/jac/dkm371

PMID:17884833

Abstract

OBJECTIVES

This study aimed to examine the peritoneal penetration of intravenous doripenem, a novel carbapenem used for the treatment of intra-abdominal infections.

PATIENTS AND METHODS

Doripenem (500 mg) was administered to 10 patients before abdominal surgery. Venous blood and peritoneal exudate samples were obtained at the end of infusion (0.5 h) and every hour for 6 h afterwards. The drug concentrations in serum and exudate were measured using HPLC, estimated by non-compartmental pharmacokinetic analysis and fitted to a three-compartment pharmacokinetic model in order to assess the exposure time that the drug concentration remained above MIC.

RESULTS

The AUC(0-infinity) was 59.3 +/- 7.2 mg.h/L (mean +/- SD) in serum and 49.3 +/- 6.5 mg.h/L in exudate, and the exudate/serum ratio was 0.84 +/- 0.13. The observed maximum concentration was 46.9 +/- 7.4 mg/L at 0.5 h in serum and 24.5 +/- 6.5 mg/L at 0.7 +/- 0.4 h in exudate, and the exudate/serum ratio was 0.53 +/- 0.17. The compartmental analysis showed that the average concentrations remained higher in exudate than in serum after 0.81 h post-dose, and the average drug-exposure times in serum (91% fraction unbound) and exudate were: 73.6% and 78.2% at an MIC of 1 mg/L; 37.0% and 41.5% at 4 mg/L; and 12.7% and 13.1% at 16 mg/L.

CONCLUSIONS

Following intravenous administration, doripenem penetrated well into peritoneal exudate of abdominal-surgery patients, and the drug-exposure times in exudate were greater than or equal to those estimated from serum data.

摘要

目的

本研究旨在检测用于治疗腹腔感染的新型碳青霉烯类药物静脉注射多利培南的腹膜穿透情况。

患者与方法

在腹部手术前，对10例患者静脉注射多利培南（500毫克）。在输注结束时（0.5小时）以及之后的6小时内每小时采集静脉血和腹膜渗出液样本。采用高效液相色谱法测定血清和渗出液中的药物浓度，通过非房室药代动力学分析进行估算，并拟合三室药代动力学模型，以评估药物浓度保持在最低抑菌浓度（MIC）以上的暴露时间。

结果

血清中的AUC(0-无穷大)为59.3±7.2毫克·小时/升（平均值±标准差），渗出液中的为49.3±6.5毫克·小时/升，渗出液/血清比值为0.84±0.13。血清中在0.5小时观察到的最大浓度为46.9±7.4毫克/升，渗出液中在0.7±0.4小时为24.5±6.5毫克/升，渗出液/血清比值为0.53±0.17。房室分析显示，给药后0.81小时后，渗出液中的平均浓度仍高于血清中的平均浓度，血清（未结合分数为91%）和渗出液中的平均药物暴露时间分别为：在MIC为1毫克/升时为73.6%和78.2%；在4毫克/升时为37.0%和41.5%；在16毫克/升时为12.7%和13.1%。